Israel - English - Ministry of Health

tzamal bio-pharma ltd - dalbavancin - powder for concentrate for solution for infusion - dalbavancin 500 mg - dalbavancin - xydalba is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults

Israel - English - Ministry of Health

tzamal bio-pharma ltd - ganciclovir sodium - solution for injection - ganciclovir sodium 500 mg - ganciclovir - ganciclovir - cymevene iv is indicated for the treatment of cmv retinitis in immunocompromised patiens, including patients with acquired immunodeficiency syndrome (aids). cymevene iv is also indicated for the prevention of cmv disease in transplant recipients at risk for cmv disease.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - filgrastim - solution for injection / infusion - filgrastim 300 mcg / 0.5 ml - filgrastim - accofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.the safety and efficacy of accofil are similar in adults and children receiving cytotoxic chemotherapy.accofil is indicated for the mobilisation of peripheral blood progenitor cells (pbpcs).in patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of less or equal to 0.5 x 109 /l, and a history of severe or recurrent infections, long term administration of accofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.accofil is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 109 /l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - filgrastim - solution for injection / infusion - filgrastim 480 mcg / 0.5 ml - filgrastim - accofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.the safety and efficacy of accofil are similar in adults and children receiving cytotoxic chemotherapy.accofil is indicated for the mobilisation of peripheral blood progenitor cells (pbpcs).in patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of less or equal to 0.5 x 109 /l, and a history of severe or recurrent infections, long term administration of accofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.accofil is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 109 /l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - filgrastim - solution for injection / infusion - filgrastim 300 mcg / 0.5 ml - filgrastim - stimofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.the safety and efficacy of stimofil are similar in adults and children receiving cytotoxic chemotherapy.stimofil is indicated for the mobilisation of peripheral blood progenitor cells (pbpcs).in patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of less or equal to 0.5 x 109 /l, and a history of severe or recurrent infections, long term administration of stimofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.stimofil is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 109 /l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - filgrastim - solution for injection / infusion - filgrastim 480 mcg / 0.5 ml - filgrastim - stimofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.the safety and efficacy of stimofil are similar in adults and children receiving cytotoxic chemotherapy.stimofil is indicated for the mobilisation of peripheral blood progenitor cells (pbpcs).in patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of less or equal to 0.5 x 109 /l, and a history of severe or recurrent infections, long term administration of stimofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.stimofil is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 109 /l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - pegaspargase - powder for solution for inj/inf - pegaspargase 3750 u/vial - pegaspargase - oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (all) in paediatric patients from birth to 18 years, and adult patients.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - urokinase - powder for solution for injection - urokinase 10000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - urokinase - powder for solution for injection - urokinase 50000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - urokinase - powder for solution for injection - urokinase 100,000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.